Focal segmental glomerulosclerosis (FSGS) (Dimerex)

Protocol Name: A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (Action3) Indication: Focal segmental glomerulosclerosis (FSGS) Primary Investigator: Dr. Kim Rice Location: 411 N Washington Ave, Suite 6000, Dallas, TX 75204 DETAILS >